Sign In
Buy NVS
$148.93
+1.85 (+1.26%)
At Close: Jun 22, 2026
Dividend Harvesting: Week 34 Update, $3,400 Allocated, $229.63 In Annual Dividends Yielding 6.7% With 50 Positions
09:00am, Thursday, 28'th Oct 2021
Dividend Harvesting: Week 34 Update, $3,400 Allocated, $229.63 In Annual Dividends Yielding 6.7% With 50 Positions
Novartis Ponders Fate of Its Sandoz Generics Unit
03:09pm, Wednesday, 27'th Oct 2021
Following three years of speculation, Novartis AG ( NVS , Financial) may be ready to split off its Sandoz unit. The latter, which has operated with minimal input from its parent since 2018, may gain f
Novartis CEO says company starting strategic review of Sandoz generic drug unit
04:10pm, Tuesday, 26'th Oct 2021
Vas Narasimhan, Novartis CEO, joins 'Closing Bell' to discuss the company after reporting earnings. Narasimhan and CNBC's Sara Eisen discuss a wide range of topics; from a strategic review of its gene
Is Eli Lilly or Novartis the better buy after Q3 results?
03:58pm, Tuesday, 26'th Oct 2021
On Monday, Eli Lilly And Co (NYSE:LLY) and Novartis AG (OTCMKTS:NVSEF) shares edged higher after announcing their most recent quarterly results. Eli Lilly's revenue and earnings missed expectations wh
Novartis AG (NVS) CEO Vas Narasimhan on Q3 2021 Results - Earnings Call Transcript
01:30pm, Tuesday, 26'th Oct 2021
Novartis AG (NVS) CEO Vas Narasimhan on Q3 2021 Results - Earnings Call Transcript
Novartis: Q3 Earnings Insights
08:36am, Tuesday, 26'th Oct 2021
Novartis (NYSE:NVS) reported its Q3 earnings results on Tuesday, October 26, 2021 at 08:00 AM. Here's what investors need to know about the announcement.
Novartis reports rise in sales and earnings, backs guidance
01:34am, Tuesday, 26'th Oct 2021
Corrections & Amplifications
Novartis more bullish on Cosentyx, Entresto sales as Q3 profit rises
01:26am, Tuesday, 26'th Oct 2021
Novartis's third-quarter adjusted operating profit rose 10% as the Swiss drugmaker lifted its peak sales estimate for its two most important pharmaceuticals.
Novartis lung cancer drug doesn't meet primary endpoints in late trial
01:36am, Monday, 25'th Oct 2021
Novartis AG said Monday that a Phase 3 trial to evaluate a drug for use in lung cancer patients didn't meet its primary endpoints.
Novartis Is Cheap, AA-Rated Pharma - It's Time To 'Buy'
09:11pm, Sunday, 24'th Oct 2021
Novartis Is Cheap, AA-Rated Pharma - It's Time To 'Buy'
5 Top Goldman Sachs European Stock Picks Come With Big Dividends
07:37am, Thursday, 21'st Oct 2021
Recently, the risk-off crowd has pushed the market higher following some stellar third-quarter earnings.
Novartis Extends Fill/Finish Support For Pfizer/BioNTech COVID-19 Vaccines
07:02am, Thursday, 21'st Oct 2021
Novartis AG (NYSE: NVS) has agreed to expand its fill-and-finish support for Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) COVID-19 vaccine. Novartis will use its sterile manufacturing fa
Novartis signs new agreement with BioNTech to help manufacture COVID vaccines
02:12am, Thursday, 21'st Oct 2021
Novartis AG said Thursday that it has signed a new agreement with BioNTech SE to support the production of the company's and Pfizer Inc.'s Covid-19 vaccine at one of its facilities.
Is This Beaten Down Biotech a Bad News Buy?
07:00am, Wednesday, 20'th Oct 2021
It has lagged the market over the last five years but with a promising gene therapy, is Sarepta worth another look?
5 High-Yield Dividend Aristocrats That Are Perfect For Sinking Markets
01:43pm, Wednesday, 13'th Oct 2021
The debt ceiling crisis has helped cause a healthy pullback but could result in a 10% to 20% correction in the next few weeks.
